Loa loa—does it deserve to be neglected?

Brain, 1931, Loa-Loa, Proc R Soc Med, 24, 515 Mongin, 1770, Sur un ver trouvé sous la conjonctive à Maribarou, isle Saint-Dominique, J Med Chir Pharm Paris, 32, 338 Zouré, 2011, The geographic distribution of Loa loa in Africa: results of large-scale implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA), PLoS Negl Trop Dis, 5, e1210, 10.1371/journal.pntd.0001210 Boulesteix, 1986, Encephalite au cours du traitment de la filariose a Loa loa par la diethylcarbamazine. A propos de 6 observations, Bull Soc Pathol Exot, 79, 649 Pinder, 1988, Loa loa—a neglected filaria, Parasitol Today, 4, 279, 10.1016/0169-4758(88)90019-1 Elliot, 1918, Removal of worm (filaria loa) from the eye, BMJ, 1, 502, 10.1136/bmj.1.2992.502 Grobusch, 2003, No evidence of Wolbachia endosymbiosis with Loa loa and Mansonella perstans, Parasitol Res, 90, 405, 10.1007/s00436-003-0872-z Büttner, 2003, Obligatory symbiotic Wolbachia endobacteria are absent from Loa loa, Filaria J, 2, 10, 10.1186/1475-2883-2-10 McGarry, 2003, Evidence against Wolbachia symbiosis in Loa loa, Filaria J, 2, 9, 10.1186/1475-2883-2-9 Bourguinat, 2010, Analysis of the mdr-1 gene in patients co-infected with Onchocerca volvulus and Loa loa who experienced a post-ivermectin serious adverse event, Am J Trop Med Hyg, 83, 28, 10.4269/ajtmh.2010.09-0734 Turner, 2010, Macrofilaricidal activity after doxycycline only treatment of Onchocerca volvulus in an area of Loa loa co-endemicity: a randomized controlled trial, PLoS Negl Trop Dis, 4, e660, 10.1371/journal.pntd.0000660 Twum-Danso, 2003, Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future, Filaria J, 2, S7, 10.1186/1475-2883-2-S1-S7 Duke, 2003, Overview: report of a Scientific Working Group on Serious Adverse Events following Mectizan(R) treatment of onchocerciasis in Loa loa endemic areas, Filaria J, 2, S1, 10.1186/1475-2883-2-S1-S1 2004, Report of a Scientific Working Group on Serious Adverse Events following Mectizan(R) treatment of onchocerciasis in Loa loa endemic areas, Filaria J, 2, S2 Moussala, 2004, Retinal hemorrhages after ivermectin treatment for onchocerciasis in a patient with Loa loa microfilaremia, J Fr Ophtalmol, 27, 63, 10.1016/S0181-5512(04)96094-9 Boussinesq, 1998, Three probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis, Am J Trop Med Hyg, 58, 461, 10.4269/ajtmh.1998.58.461 Gardon, 1997, Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection, Lancet, 350, 18, 10.1016/S0140-6736(96)11094-1 Wanji, 2009, Community-directed delivery of doxycycline for the treatment of onchocerciasis in areas of co-endemicity with loiasis in Cameroon, Parasit Vectors, 2, 39, 10.1186/1756-3305-2-39 Otubanjo, 2008, Adverse reactions from community directed treatment with ivermectin (CDTI) for onchocerciasis and loiasis in Ondo State, Nigeria, Rev Biol Trop, 56, 1635 Haselow, 2003, Programmatic and communication issues in relation to serious adverse events following ivermectin treatment in areas co-endemic for onchocerciasis and loiasis, Filaria J, 2, S10, 10.1186/1475-2883-2-S1-S10 Twum-Danso, 2003, Variation in incidence of serious adverse events after onchocerciasis treatment with ivermectin in areas of Cameroon co-endemic for loiasis, Trop Med Int Health, 8, 820, 10.1046/j.1365-3156.2003.01091.x Pion, 2006, Co-infection with Onchocerca volvulus and Loa loa microfilariae in central Cameroon: are these two species interacting?, Parasitology, 132, 843, 10.1017/S003118200600984X Thomson, 2004, Mapping the distribution of Loa loa in Cameroon in support of the African Programme for Onchocerciasis Control, Filaria J, 3, 7, 10.1186/1475-2883-3-7 Wanji, 2003, Epidemiology of concomitant infections due to Loa loa, Mansonella perstans, and Onchocerca volvulus in rain forest villages of Cameroon, Med Microbiol Immunol, 192, 15, 10.1007/s00430-002-0154-x Tekle, 2011, Integrated rapid mapping of onchocerciasis and loiasis in the Democratic Republic of Congo: impact on control strategies, Acta Trop, 120, S81, 10.1016/j.actatropica.2010.05.008 Wanji, 2005, Combined utilisation of Rapid Assessment Procedures for Loiasis (RAPLOA) and Onchocerciasis (REA) in rain forest villages of Cameroon, Filaria J, 4, 2, 10.1186/1475-2883-4-2 Boussinesq, 1997, Prevalences of Loa loa microfilaraemia throughout the area endemic for the infection, Ann Trop Med Parasitol, 91, 573, 10.1080/00034989760671 Akue, 2011, Epidemiology of concomitant infection due to Loa loa and Mansonella perstans in Gabon, PLoS Negl Trop Dis, 5, e1329, 10.1371/journal.pntd.0001329 Carme, 1983, Variations in microfilaremia in Loa loa filariasis, Ann Soc Belg Med Trop, 63, 333 Touré, 1998, Human occult loiasis: field evaluation of a nested polymerase chain reaction assay for the detection of occult infection, Trop Med Int Health, 3, 505, 10.1046/j.1365-3156.1998.00260.x 1995 Adinarayanan, 2007, Diethylcarbamazine (DEC)-medicated salt for community-based control of lymphatic filariasis, Cochrane Database Syst Rev, 1, 10.1002/14651858.CD003758.pub2 Awadzi, 1992, Diethylcarbamazine in the treatment of patients with onchocerciasis, Br J Clin Pharmacol, 34, 281, 10.1111/j.1365-2125.1992.tb05632.x Nutman, 1988, Diethylcarbamazine prophylaxis for human loiasis. Results of a double-blind study, N Engl J Med, 319, 752, 10.1056/NEJM198809223191204 Klion, 1994, Effectiveness of diethylcarbamazine in treating loiasis acquired by expatriate visitors to endemic regions: long-term follow-up, J Infect Dis, 169, 604, 10.1093/infdis/169.3.604 Stanley, 1982, Ascending paralysis associated with diethylcarbamazine treatment of M. Loa loa infection, Trop Doct, 12, 16, 10.1177/004947558201200107 Carme, 1991, Five cases of encephalitis during treatment of loiasis with diethylcarbamazine, Am J Trop Med Hyg, 44, 684, 10.4269/ajtmh.1991.44.684 Tabi, 2004, Human loiasis in a Cameroonian village: a double-blind, placebo-controlled, crossover clinical trial of a three-day albendazole regimen, Am J Trop Med Hyg, 71, 211, 10.4269/ajtmh.2004.71.211 Klion, 1999, Albendazole therapy for loiasis refractory to diethylcarbamazine treatment, Clin Infect Dis, 29, 680, 10.1086/598654 Blum, 2001, Encephalopathy following Loa loa treatment with albendazole, Acta Trop, 78, 63, 10.1016/S0001-706X(00)00159-5 Kamgno, 2007, Randomized, controlled, double-blind trial with ivermectin on Loa loa microfilaraemia: efficacy of a low dose versus current standard dose, Trans R Soc Trop Med Hyg, 101, 777, 10.1016/j.trstmh.2007.03.018 Martin-Prevel, 1993, Tolerance and efficacy of single high-dose ivermectin for the treatment of loiasis, Am J Trop Med Hyg, 48, 186, 10.4269/ajtmh.1993.48.186 Tsague-Dongmo, 2002, Effects of a 3-day regimen of albendazole (800 mg daily) on Loa loa microfilaraemia, Ann Trop Med Parasitol, 96, 707, 10.1179/000349802125001933 Kamgno, 2002, Effect of a single dose (600 mg) of albendazole on Loa loa microfilaraemia, Parasite, 9, 59, 10.1051/parasite/200209159 Klion, 1993, Albendazole in human loiasis: results of a double-blind, placebo-controlled trial, J Infect Dis, 168, 202, 10.1093/infdis/168.1.202 Boussinesq, 2012, Loiasis: new epidemiologic insights and proposed treatment strategy, J Travel Med, 19, 140, 10.1111/j.1708-8305.2012.00605.x Saeed, 1984, Loa loa: the use of a blood cell separator to reduce microfilaraemia before specific chemotherapy, J Infect, 9, 161, 10.1016/S0163-4453(84)91195-2 Kern, 1988, Continuous-flow apheresis of microfilariae in Loa loa infestations, Plasma Ther Transfus, 9, 95, 10.1016/0278-6222(88)90040-X Muylle, 1983, Usefulness of apheresis to extract microfilarias in management of loiasis, BMJ, 287, 519, 10.1136/bmj.287.6391.519 Nutman, 1986, Loa loa infection in temporary residents of endemic regions: recognition of a hyperresponsive syndrome with characteristic clinical manifestations, J Infect Dis, 154, 10, 10.1093/infdis/154.1.10 Boussinesq, 2006, Loiasis, Ann Trop Med Parasitol, 100, 715, 10.1179/136485906X112194 Carme, 1989, Clinical and biological study of Loa loa filariasis in Congolese, Am J Trop Med Hyg, 41, 331, 10.4269/ajtmh.1989.41.331 Noireau, 1990, Clinical manifestations of loiasis in an endemic area in the Congo, Trop Med Parasitol, 41, 37 Takougang, 2007, Loiasis—a neglected and under-estimated affliction: endemicity, morbidity and perceptions in eastern Cameroon, Ann Trop Med Parasitol, 101, 151, 10.1179/136485907X154511 Tenaguem, 2010, Cardiac lesions in an area hyperendemic for loiasis in Cameroun, Am J Trop Med Hygiene, 83, 1330 Tenaguem J. Manifestations cardiaques de la filariose à Loa loa dans le district de santé d'Akonolinga. Master's thesis, Faculté de Médecine et des Sciences Biomédicales, Université de Yaoundé I, 2010. Klion, 1991, Loiasis in endemic and nonendemic populations: immunologically mediated differences in clinical presentation, J Infect Dis, 163, 1318, 10.1093/infdis/163.6.1318 Churchill, 1996, Clinical and laboratory features of patients with loiasis (Loa loa filariasis) in the UK, J Infect, 33, 103, 10.1016/S0163-4453(96)93005-4 Lorcy A. Recherche anthropologique menée dans une équipe interdisciplinaire (épidémiologie, entomologie, anthropologie) sur la maladie endémique loase (filariose) chez les Elog Mpoo du Sud Cameroun Rapport: La loase, un problème de santé publique au Cameroun? Une étude de cas chez les Elog Mpoo. IRD/Centre Pasteur de Yaoundé 2001. Ugwendum Fan D. The prevalence and impact of loiasis at the community level in the Ebolowa Health District. PhD thesis, Faculté de Médecine et des Sciences Biomédicales, Université de Yaoundé I, 2008. Kamtchum Tatuene J. Profil épidémiologique de la loase et évaluation de son impact ophtalmologique dans le District de Santé d'Akonolinga. PhD thesis, Faculté de Médecine et des Sciences Biomédicales, Université de Yaoundé I, 2010. Carme, 2012, Rapid assessment procedure for loiasis and mapping lymphatic filariasis: two perfect illustrations of “to be in English or not to be”, PLoS Negl Trop Dis, 6, e1863, 10.1371/journal.pntd.0001863 2002 2009 Hotez, 2011, Enlarging the “Audacious Goal”: elimination of the world's high prevalence neglected tropical diseases, Vaccine, 29, D104, 10.1016/j.vaccine.2011.06.024